T2 Biosystems, which is developing diagnostics tests that screen for sepsis and hemostasis, announced terms for its IPO on Monday. The Lexington, MA-based company plans to raise $64 million by offering 4.0 million shares at a price range of $15 to $17. At the midpoint of the proposed range, T2 would command a fully diluted market value of $321 million.
T2 Biosystems, which was founded in 2006, plans to list on the NASDAQ under the symbol TTOO. Goldman Sachs and Morgan Stanley are the joint bookrunners on the deal. It is expected to price during the week of August 4, 2014.
